


## Glimepiride-d5

Cat. No.:	HY-B0104S
CAS No.:	1028809-90-6
Molecular Formula:	C <sub>24</sub> H <sub>29</sub> D <sub>5</sub> N <sub>4</sub> O <sub>3</sub> S
Molecular Weight:	495.65
Target:	Amyloid-β; Isotope-Labeled Compounds
Pathway:	Neuronal Signaling; Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Glimepiride-d5 is the deuterium labeled Glimepiride. Glimepiride (Glimperide) is a medium-to-long acting sulfonylurea anti-diabetic compound with an ED <sub>50</sub> of 182 µg/kg.
<b>In Vitro</b>	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother*. 2019;53(2):211-216.
- [2]. Geisen, K., Special pharmacology of the new sulfonylurea glimepiride. *Arzneimittelforschung*, 1988. 38(8): p. 1120-30.
- [3]. Liu, F., et al., Glimepiride attenuates Abeta production via suppressing BACE1 activity in cortical neurons. *Neurosci Lett*, 2013. 557 Pt B: p. 90-4.
- [4]. Basit, A., M. Riaz, and A. Fawwad, Glimepiride: evidence-based facts, trends, and observations (GIFTS). [corrected]. *Vasc Health Risk Manag*, 2012. 8: p. 463-72.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA